Overview

Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
Phase II trial to study the effectiveness of combining oxaliplatin, fluorouracil and leucovorin in treating patients who have metastatic colorectal cancer that has been previously treated with irinotecan. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Calcium
Fluorouracil
Irinotecan
Leucovorin
Levoleucovorin
Oxaliplatin
Criteria
DISEASE CHARACTERISTICS:

- Diagnosis of metastatic colorectal adenocarcinoma incurable by surgery or not amenable
to radiotherapy with curative intent

- Progressive disease no more than 3 months after completion of a prior weekly
irinotecan, fluorouracil, and leucovorin calcium chemotherapy regimen

- At least 1 measurable lesion At least 20 mm in at least one dimension

- No known CNS metastases or carcinomatous meningitis

PATIENT CHARACTERISTICS:

- Age: 18 and over

- Performance status: ECOG 0-2

- Life expectancy: At least 12 weeks

- Absolute neutrophil count greater than 2,000/mm3

- Platelet count at least 100,000/mm3

- Bilirubin no greater than 0.5 mg/dL above upper limit of normal (ULN)

- AST no greater than 5 times ULN

- Creatinine no greater than 1.5 times ULN OR creatinine clearance greater than 60
mL/min

- No unstable angina No symptomatic congestive heart failure

- No serious uncontrolled cardiac arrhythmia

- No active or uncontrolled infection

- No evidence of other serious illness

- No other malignancy within the past 5 years except adequately treated basal cell or
squamous cell skin cancer or noninvasive carcinomas

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

- No concurrent sargramostim (GM-CSF)

- At least 4 weeks since prior chemotherapy

- No more than 1 prior chemotherapy regimen for advanced colorectal cancer

- Prior adjuvant chemotherapy allowed

- No prior radiotherapy to more than 25% of bone marrow

- At least 4 weeks since prior major surgery